View Post

Tumor ‘Paint’ Aids Breast Cancer Surgeons and Well-Tolerated by Patients, Study Reports

In In The News by Barbara Jacoby

By: Janet Stewart, MSc From: breastcancer-news.com BLZ-100 (tozuleristide) was found to be well-tolerated by patients and to make breast cancer tumors more easily seen during surgery in a Phase 1 clinical trial, Blaze Bioscience announced. BLZ-100 was used to “paint” tumors to better guide surgeons while operating. Results of the trial (NCT02496065) were presented at the American Society of Breast Surgeons …

View Post

Fox Chase Enrolling Patients in ONC201 Multiple Myeloma Trial

In In The News by Barbara Jacoby

Oncoceutics, Inc. announced that the first patient has begun treatment in a clinical trial of the company’s lead compound, ONC201, at the Fox Chase Cancer Center (FCCC) in relapsed/refractory multiple myeloma. The Phase I/II trial, identified as NCT02863991 on www.clinicaltrials.gov, will investigate the use of ONC201 in combination with dexamethasone in adult patients with multiple myeloma who have relapsed or …

View Post

Trial Of Immune Drug In Breast Cancer Points To Need For Biomarkers

In In The News by Barbara Jacoby

By: Elaine Schattner From: forbes.com At first glance, results with a powerful immune agent in breast cancer appear negative. In an early-phase clinical trial, only 10% of patients with metastatic disease responded to atezolizumab (Tecentriq). Yet for those few women who did respond, the benefit was dramatic. Among 112 women with evaluable, advanced disease, 11 have experienced durable responses lasting …

View Post

High-dose vitamin C makes cancer treatment more effective, trial shows

In In The News by Barbara Jacoby

By: Ana Sandolu From: medicalnewstoday.com Common treatment options for cancer, such as chemotherapy and radiation therapy, can be expensive and sometimes ineffective. However, a new clinical trial tests the effect of high-dose vitamin C in combination with standard treatment on health outcomes for patients with cancer. In the 1970s and 1980s, Nobel Prize winner Linus Pauling, together with surgeon Ewan …

View Post

Breast Cancer Vaccine Personalized

In In The News by Barbara Jacoby

By: Bianca Castro From: nbcdfw.com Breast cancer is the second most common cancer in American women. More than 300,000 women will be diagnosed this year. Researchers are working on a vaccine that could lead to prevention. “Your general practitioner who normally says ‘everything is fine’ goes pale,” said Barbara Popoli, while speaking in front of lawmakers to push for more …

View Post

Clinical trial for pediatric cancer drug now has N.J. openings

In In The News by Barbara Jacoby

By: Kathleen O’Brien | NJ Advance Media for NJ.com From: nj.com A national clinical trial for an unorthodox drug to treat a cancer that strikes very young children now has openings in New Jersey, thanks to a foundation. The Phase 2 trial for a medication to treat neuroblastoma recently added Hackensack University Medical Center as a research site – one of …

View Post

Scientists To Trial Personalized Vaccine Against One Type Of Cancer

In In The News by Barbara Jacoby

By: Alfredo Carpineti From: iflscience.com Researchers are starting a ground-breaking clinical trial that will use a patient’s own tumor and immune cells to fight the reoccurrence of a type of blood cancer known as multiple myeloma. The trial will be led by the University of Wisconsin Carbone Cancer Center and conducted by 14 other different cancer research centers. It will …

View Post

Ongoing Clinical Trial Seeks Participation from Hispanic Patients Living With Advanced Breast Cancer

In In The News by Barbara Jacoby

Phase III EMBRACA Clinical Trial Currently Enrolling Hispanic Individuals – Particularly of Mexican and Puerto Rican Descent — due to Higher Prevalence of BRCA Mutation What:     Breast cancer is the most commonly diagnosed cancer in Hispanic women and the continued leading cause of cancer death. The EMBRACA clinical trial is studying the safety and efficacy of an investigational drug, talazoparib, …

View Post

ONC201 Continues to Show Excellent Safety When Dosed Weekly

In In The News by Barbara Jacoby

Oncoceutics, Inc. announced the successful completion of the dose escalation phase of a clinical trial for the company’s lead molecule ONC201 using weekly dosing.  Oncoceutics has previously reported the exceptional safety profile for ONC201 in multiple clinical trials using a dosing regimen of once every three weeks. The weekly cohort was part of a trial entitled “Oral ONC201 in Treating …

View Post

Blood test launched that monitors the cancer’s ‘DNA’

In In The News by Barbara Jacoby

By: Stephen Matthews From: dailymail.co.uk A new ‘smart blood test’ could revolutionise cancer treatment by matching patients to the most effective care earlier. Liquid biopsies, which would cost between £200 and £300, could become a standard part of patient care within just two years, experts believe. A groundbreaking clinical trial involving 1,000 breast cancer patients will be launched in the …